Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Atara Biotherapeutics $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common…
CytomX Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc…
BioXcel Therapeutics $73.6 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300…
Revolution Medicines $273.7 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of…
Revance Therapeutics $287.5 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5…
Shockwave Medical $16.5 million supplemental term loan
Davis Polk advised Shockwave Medical, Inc. in connection with a $16.5 million supplemental term loan provided by Silicon…
Theravance Biopharma $148.5 million follow-on offering
Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by…
Innovent Biologics HK$2.4 billion placing of shares
Davis Polk advised the sole placing agent for the primary placement of an aggregate of 78,000,000 new shares in Innovent…
Applied Genetic Technologies stock offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6…
RAPT Therapeutics $75 million follow-on offering
Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT…